

# Amã-lcar Falcã£o

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4241371/publications.pdf>

Version: 2024-02-01

218  
papers

7,430  
citations

81434

41  
h-index

87275

74  
g-index

220  
all docs

220  
docs citations

220  
times ranked

10042  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-Inflammatory and Antiproliferative Properties of Sweet Cherry Phenolic-Rich Extracts. <i>Molecules</i> , 2022, 27, 268.	1.7	10
2	10 <sup>12</sup> -Hydroxyestra-1,4-diene-3,17-dione as potential antiproliferative agent: in vitro biological evaluation and in silico studies. <i>Natural Product Research</i> , 2022, 36, 6459-6463.	1.0	0
3	Editorial: Intranasal Drug Delivery: Challenges and Opportunities. <i>Frontiers in Pharmacology</i> , 2022, 13, 868986.	1.6	7
4	Mineral Content and Volatile Profiling of <i>Prunus avium</i> L. (Sweet Cherry) By-Products from Fundão Region (Portugal). <i>Foods</i> , 2022, 11, 751.	1.9	7
5	C-Ring Oxidized Estrone Acetate Derivatives: Assessment of Antiproliferative Activities and Docking Studies. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 3579.	1.3	0
6	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future. <i>Ageing Research Reviews</i> , 2022, 77, 101612.	5.0	26
7	Effects of Functional Phenolics Dietary Supplementation on Athletes' Performance and Recovery: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4652.	1.8	14
8	Spray dried powders for nasal delivery: Process and formulation considerations. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 176, 1-20.	2.0	17
9	Self-Emulsifying Drug Delivery Systems: An Alternative Approach to Improve Brain Bioavailability of Poorly Water-Soluble Drugs through Intranasal Administration. <i>Pharmaceutics</i> , 2022, 14, 1487.	2.0	8
10	Silymarin as a flavonoid-type P-glycoprotein inhibitor with impact on the pharmacokinetics of carbamazepine, oxcarbazepine and phenytoin in rats. <i>Drug and Chemical Toxicology</i> , 2021, 44, 458-469.	1.2	15
11	Is intranasal administration an opportunity for direct brain delivery of lacosamide?. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105632.	1.9	9
12	Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview. <i>Pharmacological Research</i> , 2021, 164, 105309.	3.1	12
13	A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. <i>International Journal of Pharmaceutics</i> , 2021, 593, 120161.	2.6	15
14	Development and application of an HPLC-DAD technique for human plasma concentration monitoring of perampanel and lamotrigine in drug-resistant epileptic patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1162, 122491.	1.2	10
15	HPLC method for the determination of antiepileptic drugs in human saliva and its application in therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 197, 113961.	1.4	7
16	Exosomes as new therapeutic vectors for pancreatic cancer treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 161, 4-14.	2.0	13
17	Valorisation of <i>Prunus avium</i> L. By-Products: Phenolic Composition and Effect on Caco-2 Cells Viability. <i>Foods</i> , 2021, 10, 1185.	1.9	19
18	New Estrone Oxime Derivatives: Synthesis, Cytotoxic Evaluation and Docking Studies. <i>Molecules</i> , 2021, 26, 2687.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. <i>Life Sciences</i> , 2021, 275, 119342.	2.0	18
20	Dietary Effects of Anthocyanins in Human Health: A Comprehensive Review. <i>Pharmaceutics</i> , 2021, 14, 690.	1.7	93
21	<i>Prunus avium</i> L. (Sweet Cherry) By-Products: A Source of Phenolic Compounds with Antioxidant and Anti-Hyperglycemic Propertiesâ€”A Review. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8516.	1.3	16
22	Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10745.	1.8	19
23	Hepatoprotective Effects of Sweet Cherry Extracts (cv. Saco). <i>Foods</i> , 2021, 10, 2623.	1.9	9
24	Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression. <i>Pharmaceutics</i> , 2021, 13, 1975.	2.0	12
25	Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation. <i>Frontiers in Pharmacology</i> , 2021, 12, 751321.	1.6	8
26	Safety evidence on the administration of <i>Fucus vesiculosus</i> L. (bladderwrack) extract and lamotrigine: data from pharmacokinetic studies in the rat. <i>Drug and Chemical Toxicology</i> , 2020, 43, 560-566.	1.2	3
27	Repairing blood-CNS barriers: Future therapeutic approaches for neuropsychiatric disorders. <i>Pharmacological Research</i> , 2020, 162, 105226.	3.1	3
28	Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. <i>Pharmaceutics</i> , 2020, 12, 943.	2.0	3
29	Peptide-lipid nanoconstructs act site-specifically towards glioblastoma growth impairment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 155, 177-189.	2.0	13
30	Saltingâ€”assisted liquidâ€”liquid extraction method optimized by design of experiments for the simultaneous highâ€”performance liquid chromatography analysis of perampanel and stiripentol in mouse matrices. <i>Journal of Separation Science</i> , 2020, 43, 4289-4304.	1.3	9
31	Cystic fibrosis: Physiopathology and the latest pharmacological treatments. <i>Pharmacological Research</i> , 2020, 162, 105267.	3.1	12
32	Clinical pharmacists' interventions in the management of type 2 diabetes mellitus: a systematic review. <i>Pharmacy Practice</i> , 2020, 18, 2000.	0.8	13
33	QbD-driven development of intranasal lipid nanoparticles for depression treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 153, 106-120.	2.0	29
34	Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial. <i>Epilepsy and Behavior</i> , 2020, 105, 106962.	0.9	16
35	Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration. <i>Pharmaceutical Research</i> , 2020, 37, 74.	1.7	13
36	Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. <i>Pharmaceutics</i> , 2020, 12, 158.	2.0	63

#	ARTICLE	IF	CITATIONS
37	Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics. <i>British Journal of Pharmacology</i> , 2020, 177, 2215-2239.	2.7	46
38	Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 181, 113109.	1.4	41
39	Improving the drug-likeness of inspiring natural products - evaluation of the antiparasitic activity against <i>Trypanosoma cruzi</i> through semi-synthetic and simplified analogues of licarin A. <i>Scientific Reports</i> , 2020, 10, 5467.	1.6	23
40	In-Depth Analysis of the Impact of Different Serum-Free Media on the Production of Clinical Grade Dendritic Cells for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 593363.	2.2	7
41	Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders. <i>Current Pharmaceutical Design</i> , 2020, 26, 594-619.	0.9	17
42	$\Delta^{9,11}$ -Estrone derivatives as potential antiproliferative agents: synthesis, in vitro biological evaluation and docking studies. , 2020, 23, 201-217.		3
43	Real-world clinical characterization of subjects with depression treated with antidepressant drugs focused on (non-)genetic factors, pharmacokinetics, and clinical outcomes: GnG-PK/PD-AD study.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 202-215.	1.3	2
44	Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 589-600.	1.3	10
45	Novel bioanalytical method for the quantification of rufinamide in mouse plasma and tissues using HPLC-UV: A tool to support pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1124, 340-348.	1.2	9
46	Effectiveness of an intervention to improve antibiotic-prescribing behaviour in primary care: a controlled, interrupted time-series study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2788-2796.	1.3	16
47	Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients. <i>BMC Anesthesiology</i> , 2019, 19, 180.	0.7	1
48	Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy. , 2019, 7, 238.		33
49	First-time oral administration of resveratrol-loaded layer-by-layer nanoparticles to rats – a pharmacokinetics study. <i>Analyst</i> , 2019, 144, 2062-2079.	1.7	25
50	Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. <i>Drug Discovery Today</i> , 2019, 24, 1911-1923.	3.2	23
51	Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	9
52	Nose-to-brain delivery of levetiracetam after intranasal administration to mice. <i>International Journal of Pharmaceutics</i> , 2019, 564, 329-339.	2.6	40
53	ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches. <i>Pharmacological Research</i> , 2019, 144, 357-376.	3.1	49
54	Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review. <i>Analytica Chimica Acta</i> , 2019, 1076, 18-31.	2.6	24

#	ARTICLE	IF	CITATIONS
55	Short-term effects of <i>Garcinia cambogia</i> extract on the pharmacokinetics of lamotrigine given as a single-dose in Wistar rats. <i>Food and Chemical Toxicology</i> , 2019, 128, 61-67.	1.8	7
56	Population Pharmacokinetic-Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS). <i>Journal of Clinical Pharmacology</i> , 2019, 60, 617.	1.0	10
57	Rethinking carbamazepine oral delivery using polymer-lipid hybrid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2019, 554, 352-365.	2.6	43
58	Synthesis, in vitro evaluation and QSAR modelling of potential antitumoral 3,4-dihydropyrimidin-2-(1H)-thiones. <i>Arabian Journal of Chemistry</i> , 2019, 12, 5086-5102.	2.3	12
59	Development of a novel dendritic cell-based immunotherapy targeting cancer stem cells.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14009-e14009.	0.8	2
60	In vitro assessment of the interactions of dopamine $\beta$ -hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 35-40.	1.9	9
61	Development and validation of an HPLC-FLD technique for colistin quantification and its plasma monitoring in hospitalized patients. <i>Analytical Methods</i> , 2018, 10, 389-396.	1.3	7
62	Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma. <i>Bioanalysis</i> , 2018, 10, 541-557.	0.6	17
63	Effects of <i>Paullinia cupana</i> extract on lamotrigine pharmacokinetics in rats: A herb-drug interaction on the gastrointestinal tract with potential clinical impact. <i>Food and Chemical Toxicology</i> , 2018, 115, 170-177.	1.8	16
64	On ciprofloxacin concentration in chronic rhinosinusitis. <i>Acta Otorrinolaringológica Española</i> , 2018, 69, 35-41.	0.2	3
65	Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: An in vitro evaluation with focus on antiepileptic drugs. <i>Food Research International</i> , 2018, 103, 110-120.	2.9	31
66	Reliability of body weight scalars on the assessment of propofol induction dose in obese patients. <i>Acta Anaesthesiologica Scandinavica</i> , 2018, 62, 464-473.	0.7	3
67	In vitro screening of dual flavonoid combinations for reversing P-glycoprotein-mediated multidrug resistance: Focus on antiepileptic drugs. <i>Food and Chemical Toxicology</i> , 2018, 111, 84-93.	1.8	15
68	Considerations and Pitfalls in Selecting the Drug Vehicles for Evaluation of New Drug Candidates: Focus on in vivo Pharmacotoxicological Assays Based on the Rotarod Performance Test. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 110-118.	0.9	10
69	Evaluation of the effects of <i>Citrus aurantium</i> (bitter orange) extract on lamotrigine pharmacokinetics: Insights from in vivo studies in rats. <i>Food and Chemical Toxicology</i> , 2018, 121, 166-172.	1.8	3
70	In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. <i>Epilepsy Research</i> , 2018, 146, 63-86.	0.8	33
71	Steroidal Oximes: Useful Compounds with Antitumor Activities. <i>Current Medicinal Chemistry</i> , 2018, 25, 660-686.	1.2	28
72	Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective. <i>Current Drug Metabolism</i> , 2018, 19, 1021-1041.	0.7	7

#	ARTICLE	IF	CITATIONS
73	Rationale on the decision-making process for opicapone's bedtime regimen in Parkinson's disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-14-36.	0.0	0
74	Determination of catecholamines and endogenous related compounds in rat brain tissue exploring their native fluorescence and liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1049-1050, 51-59.	1.2	19
75	Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. EBioMedicine, 2017, 21, 123-130.	2.7	8
76	Influence of the dual combination of silymarin and (-)-epigallocatechin gallate, natural dietary flavonoids, on the pharmacokinetics of oxcarbazepine in rats. Food and Chemical Toxicology, 2017, 106, 446-454.	1.8	12
77	Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat. Toxicology and Applied Pharmacology, 2017, 323, 9-15.	1.3	5
78	Early preclinical evaluation of dihydropyrimidin(thi)ones as potential anticonvulsant drug candidates. European Journal of Pharmaceutical Sciences, 2017, 102, 264-274.	1.9	17
79	Screening of pharmacokinetic properties of fifty dihydropyrimidin(thi)one derivatives using a combo of in vitro and in silico assays. European Journal of Pharmaceutical Sciences, 2017, 109, 334-346.	1.9	9
80	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-<i>O</i>-Methyltransferase Inhibitors. Drug Metabolism and Disposition, 2017, 45, 1282-1291.	1.7	19
81	A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat. Neuropharmacology, 2017, 125, 146-155.	2.0	6
82	Intranasal Delivery of Topically-Acting Levofloxacin to Rats: a Proof-of-Concept Pharmacokinetic Study. Pharmaceutical Research, 2017, 34, 2260-2269.	1.7	5
83	Therapeutic Drug Monitoring of Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by Packed Sorbent Coupled to Liquid Chromatography. Journal of Analytical Toxicology, 2017, 41, 631-638.	1.7	20
84	Dendritic cell-based immunotherapy: a basic review and recent advances. Immunologic Research, 2017, 65, 798-810.	1.3	158
85	Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. British Journal of Clinical Pharmacology, 2017, 83, 540-553.	1.1	14
86	Intranasal delivery of ciprofloxacin to rats: A topical approach using a thermoreversible in situ gel. European Journal of Pharmaceutical Sciences, 2017, 97, 30-37.	1.9	18
87	Determination of lamotrigine in human plasma and saliva using microextraction by packed sorbent and high performance liquid chromatography-diode array detection: An innovative bioanalytical tool for therapeutic drug monitoring. Microchemical Journal, 2017, 130, 221-228.	2.3	35
88	Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders. Mini-Reviews in Medicinal Chemistry, 2017, 17, 486-517.	1.1	24
89	Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology. Phytochemistry Reviews, 2016, 15, 51-85.	3.1	70
90	Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 520.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 493-515.	0.5	108
92	Development of a liquid chromatography assay for the determination of opicapone and BIA 9â€“1079 in rat matrices. <i>Biomedical Chromatography</i> , 2016, 30, 312-322.	0.8	6
93	A Rapid and Sensitive HPLCâ€“DAD Assay to Quantify Lamotrigine, Phenytoin and Its Main Metabolite in Samples of Cultured HepaRG Cells. <i>Journal of Chromatographic Science</i> , 2016, 54, 1352-1358.	0.7	5
94	Development and application of an ex vivo fosphenytoin nasal bioconversion/permeability evaluation method. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 89, 61-72.	1.9	12
95	<i>Gastrodia elata</i> and epilepsy: Rationale and therapeutic potential. <i>Phytomedicine</i> , 2016, 23, 1511-1526.	2.3	54
96	An easy-to-use liquid chromatography assay for the analysis of lamotrigine in rat plasma and brain samples using microextraction by packed sorbent: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1035, 67-75.	1.2	13
97	Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 150-161.	0.8	22
98	Potential antitumoral 3,4-dihydropyrimidin-2-(1H)-ones: synthesis, in vitro biological evaluation and QSAR studies. <i>RSC Advances</i> , 2016, 6, 84943-84958.	1.7	21
99	Effect of 3 Singleâ€“Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catecholâ€“Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 232-240.	0.8	29
100	HPLCâ€“DAD Method for the Quantification of Carbamazepine, Oxcarbazepine and their Active Metabolites in HepaRG Cell Culture Samples. <i>Chromatographia</i> , 2016, 79, 581-590.	0.7	8
101	Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 459-467.	0.8	21
102	Determinants of physician antibiotic prescribing behavior: a 3 year cohort study in Portugal. <i>Current Medical Research and Opinion</i> , 2016, 32, 949-957.	0.9	32
103	A new PAMPA model using an in-house brain lipid extract for screening the bloodâ€“brain barrier permeability of drug candidates. <i>International Journal of Pharmaceutics</i> , 2016, 501, 102-111.	2.6	41
104	Antitumor dendritic cellâ€“based vaccines: lessons from 20Â“years of clinical trials and future perspectives. <i>Translational Research</i> , 2016, 168, 74-95.	2.2	116
105	Drug-metabolizing Enzymes and Efflux Transporters in Nasal Epithelium: Influence on the Bioavailability of Intranasally Administered Drugs. <i>Current Drug Metabolism</i> , 2016, 17, 628-647.	0.7	39
106	Cardiac safety profile of etamicastat, a novel peripheral selective dopamine-âˆ“2-hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. <i>IJC Metabolic &amp; Endocrine</i> , 2015, 7, 10-24.	0.5	4
107	2.1 Pharmacokinetics and Bioanalysis to Improve Drug Development. , 2015, , 62-118.		0
108	Physiciansâ€™ attitudes and knowledge concerning antibiotic prescription and resistance: questionnaire development and reliability. <i>BMC Infectious Diseases</i> , 2015, 16, 7.	1.3	43

#	ARTICLE	IF	CITATIONS
109	Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 454-462.	0.8	16
110	Clinical drug-drug interactions: focus on venlafaxine. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 3-17.	0.3	14
111	Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice. <i>International Journal of Pharmaceutics</i> , 2015, 490, 39-46.	2.6	56
112	Use of off-label and unlicensed drugs in hospitalised paediatric patients: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1-13.	0.8	90
113	Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. <i>Journal of Affective Disorders</i> , 2015, 174, 70-82.	2.0	19
114	Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology. <i>Phytochemistry Reviews</i> , 2015, 14, 233-272.	3.1	38
115	First MEPS/HPLC assay for the simultaneous determination of venlafaxine and <i>O</i> -desmethylvenlafaxine in human plasma. <i>Bioanalysis</i> , 2014, 6, 3025-3038.	0.6	10
116	Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 129-141.	0.3	34
117	Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application. <i>Biomedical Chromatography</i> , 2014, 28, 27-58.	0.8	33
118	Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: A review. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 87, 409-432.	2.0	222
119	Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 8-27.	2.0	149
120	Intranasal administration of carbamazepine to mice: A direct delivery pathway for brain targeting. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 60, 32-39.	1.9	76
121	Liquid chromatographic assay based on microextraction by packed sorbent for therapeutic drug monitoring of carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin and the active metabolites carbamazepine-10,11-epoxide and licarbazepine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 971, 20-29.	1.2	51
122	HepaRG cell line as an in vitro model for screening drug-drug interactions mediated by metabolic induction: Amiodarone used as a model substance. <i>Toxicology in Vitro</i> , 2014, 28, 1531-1535.	1.1	11
123	Effect of moderate liver impairment on the pharmacokinetics of opicapone. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 279-286.	0.8	27
124	Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1059-1071.	0.8	58
125	Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles. <i>Current Drug Safety</i> , 2014, 9, 89-105.	0.3	46
126	First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 930, 104-111.	1.2	34



#	ARTICLE	IF	CITATIONS
127	Bioequivalence of Eslicarbazepine Acetate from Two Different Sources of its Active Product Ingredient in Healthy Subjects. <i>Drugs in R and D</i> , 2013, 13, 137-143.	1.1	2
128	Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: New set of data for predictive in silico ADME models. <i>Epilepsy Research</i> , 2013, 107, 37-50.	0.8	30
129	Nose as a Route for Drug Delivery. , 2013, , 191-215.		2
130	Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. <i>Epilepsia</i> , 2013, 54, 1453-1461.	2.6	38
131	Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2013, 52, 139-151.	1.6	79
132	A Rapid HPLC Method for the Simultaneous Determination of Amiodarone and its Major Metabolite in Rat Plasma and Tissues: A Useful Tool for Pharmacokinetic Studies. <i>Journal of Chromatographic Science</i> , 2013, 51, 361-370.	0.7	19
133	Opicapone: a short lived and very long acting novel catecholâ€methyltransferase inhibitor following multiple dose administration in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 763-775.	1.1	76
134	Investigating herbâ€drug interactions: The effect of Citrus aurantium fruit extract on the pharmacokinetics of amiodarone in rats. <i>Food and Chemical Toxicology</i> , 2013, 60, 153-159.	1.8	13
135	Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. <i>Epilepsy Research</i> , 2013, 105, 368-376.	0.8	39
136	Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study. <i>Epilepsy Research</i> , 2013, 103, 262-269.	0.8	74
137	Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. <i>Epilepsy Research</i> , 2013, 106, 244-249.	0.8	28
138	First HPLCâ€UV method for rapid and simultaneous quantification of phenobarbital, primidone, phenytoin, carbamazepine, carbamazepine-10,11-epoxide, 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine, lamotrigine, oxcarbazepine and licarbazepine in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 925, 1-9.	1.2	66
139	Steadyâ€state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. <i>Epilepsia</i> , 2013, 54, 108-116.	2.6	65
140	Efficacy and safety of eslicarbazepine acetate as addâ€on treatment in patients with focalâ€onset seizures: Integrated analysis of pooled data from doubleâ€blind phase III clinical studies. <i>Epilepsia</i> , 2013, 54, 98-107.	2.6	85
141	An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma. <i>Analyst, The</i> , 2013, 138, 2463.	1.7	9
142	Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 203-212.	1.1	347
143	Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samplesâ€A review. <i>Analytica Chimica Acta</i> , 2013, 768, 12-34.	2.6	149
144	First liquid chromatographic method for the simultaneous determination of amiodarone and desethylamiodarone in human plasma using microextraction by packed sorbent (MEPS) as sample preparation procedure. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 913-914, 90-97.	1.2	20

#	ARTICLE	IF	CITATIONS
145	Herb-drug interaction of <i>Fucus vesiculosus</i> extract and amiodarone in rats: A potential risk for reduced bioavailability of amiodarone in clinical practice. <i>Food and Chemical Toxicology</i> , 2013, 52, 121-128.	1.8	16
146	A critical review of microextraction by packed sorbent as a sample preparation approach in drug bioanalysis. <i>Bioanalysis</i> , 2013, 5, 1409-1442.	0.6	44
147	A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, <i>R</i> -carbazepine and other new chemical derivatives BIA 2024, BIA 059 and BIA 265, in mouse plasma and brain. <i>Biomedical Chromatography</i> , 2012, 26, 384-392.	0.8	15
148	Herb-Drug Interaction of <i>Paullinia cupana</i> (Guarana) Seed Extract on the Pharmacokinetics of Amiodarone in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-10.	0.5	12
149	Single-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5453), a New Dopamine 2-Hydroxylase Inhibitor, in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 156-170.	1.0	21
150	Workshop- and Telephone-Based Interventions to Improve Adverse Drug Reaction Reporting. <i>Drug Safety</i> , 2012, 35, 655-665.	1.4	43
151	Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: A review. <i>Analytica Chimica Acta</i> , 2012, 710, 17-32.	2.6	32
152	Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures. <i>CNS Drugs</i> , 2012, 26, 79-91.	2.7	58
153	Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 93-129.	1.9	69
154	Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique. <i>Epilepsia</i> , 2012, 53, 529-538.	2.6	45
155	Bioanalysis of small-molecule drugs in nasal and paranasal tissues and secretions: Current status and perspectives. <i>Open Chemistry</i> , 2012, 10, 686-702.	1.0	0
156	Optimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide Derivatives. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 530-540.	1.6	33
157	Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453). <i>Drugs in R and D</i> , 2011, 11, 127-136.	1.1	7
158	The Kinetic Profile of Vancomycin in Neonates. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 50, 1255-1260.	1.2	18
159	In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in Göttingen minipigs. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 780-785.	1.2	5
160	Pharmacokinetics and Tolerability of Etamicastat Following Single and Repeated Administration in Elderly Versus Young Healthy Male Subjects: An Open-Label, Single-Center, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2011, 33, 776-791.	1.1	15
161	A chiral HPLC-UV method for the quantification of dibenz[b,f]azepine-5-carboxamide derivatives in mouse plasma and brain tissue: Eslicarbazepine acetate, carbamazepine and main metabolites. <i>Journal of Separation Science</i> , 2011, 34, 1391-1401.	1.3	15
162	Development and validation of a fast isocratic liquid chromatography method for the simultaneous determination of norfloxacin, lomefloxacin and ciprofloxacin in human plasma. <i>Biomedical Chromatography</i> , 2011, 25, 535-541.	0.8	19

#	ARTICLE	IF	CITATIONS
163	In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol. Journal of Bioequivalence & Bioavailability, 2011, 01, .	0.1	18
164	Enantioselective Assay for Therapeutic Drug Monitoring of Eslicarbazepine Acetate: No Interference With Carbamazepine and Its Metabolites. Therapeutic Drug Monitoring, 2010, 32, 512-516.	1.0	11
165	The Kinetic Profile of Gentamicin in Premature Neonates. Journal of Pharmacy and Pharmacology, 2010, 52, 1091-1097.	1.2	25
166	Therapeutic Monitoring of Warfarin: the Appropriate Response Marker. Journal of Pharmacy and Pharmacology, 2010, 52, 1405-1410.	1.2	14
167	Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Analytical and Bioanalytical Chemistry, 2010, 397, 1605-1615.	1.9	56
168	Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clinical Therapeutics, 2010, 32, 179-192.	1.1	35
169	Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharmaceutics and Drug Disposition, 2010, 31, 362-366.	1.1	10
170	Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor. Current Medical Research and Opinion, 2010, 26, 1097-1108.	0.9	5
171	Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Current Medical Research and Opinion, 2010, 26, 1355-1362.	0.9	31
172	Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy. Biomedicine and Pharmacotherapy, 2010, 64, 130-132.	2.5	13
173	Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine- $\beta$ -Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects. Drugs in R and D, 2010, 10, 225-242.	1.1	23
174	Intranasal Drug Delivery: How, Why and What for?. Journal of Pharmacy and Pharmaceutical Sciences, 2009, 12, 288.	0.9	427
175	The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 101.	0.8	144
176	Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Clinical Therapeutics, 2009, 31, 2258-2271.	1.1	13
177	Pharmacokinetic and safety profile of <i>trans</i> -resveratrol in a rising multiple-dose study in healthy volunteers. Molecular Nutrition and Food Research, 2009, 53, S7-15.	1.5	363
178	Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundamental and Clinical Pharmacology, 2009, 23, 509-514.	1.0	26
179	Pharmacokinetics of <i>Trans</i> -resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects. Journal of Clinical Pharmacology, 2009, 49, 1477-1482.	1.0	98
180	Antibiotics in Animal Products. , 2009, , 155-179.		0

#	ARTICLE	IF	CITATIONS
181	Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 961-966.	0.8	6
182	Stereoselective disposition of <i>S</i> - and <i>R</i> -licarbazepine in mice. <i>Chirality</i> , 2008, 20, 796-804.	1.3	18
183	Disposition of eslicarbazepine acetate in the mouse after oral administration. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 529-536.	1.0	12
184	Pharmacokinetics, Efficacy, and Tolerability of Eslicarbazepine Acetate in Children and Adolescents With Epilepsy. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 966-977.	1.0	62
185	The Role of Socioeconomic Conditions and Psychological Factors in the Willingness to Volunteer for Phase I Studies. <i>Pharmaceutical Medicine</i> , 2008, 22, 367-374.	1.0	3
186	Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200mg/50mg. <i>Drugs in R and D</i> , 2008, 9, 435-446.	1.1	4
187	Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate. <i>Drugs in R and D</i> , 2008, 9, 447-454.	1.1	17
188	Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 2-18.	0.2	30
189	Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 249-256.	1.1	50
190	Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. <i>Biomedical Chromatography</i> , 2007, 21, 1127-1134.	0.8	32
191	Cyclodextrin Multicomponent Complexation and Controlled Release Delivery Strategies to Optimize the Oral Bioavailability of Vinpocetine. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 2018-2028.	1.6	28
192	Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, <i>S</i> -licarbazepine, <i>R</i> -licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. <i>Analytica Chimica Acta</i> , 2007, 596, 132-140.	2.6	29
193	Performance of gentamicin population kinetic parameters in Portuguese neonates. <i>International Journal of Clinical Pharmacy</i> , 2007, 29, 104-108.	1.4	6
194	Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 737-742.	0.8	11
195	Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 669-675.	1.0	30
196	Single-Dose and Steady-State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093) in Healthy Elderly and Young Subjects. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1062-1066.	1.0	104
197	Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093). <i>Drugs in R and D</i> , 2005, 6, 201-206.	1.1	48
198	Eslicarbazepine Acetate (BIA 2-093). <i>Drugs in R and D</i> , 2005, 6, 253-260.	1.1	19

#	ARTICLE	IF	CITATIONS
199	CA 125 half-life breakpoint between a "good" and "poor" prognosis in patients with ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2005, 88, 333-335.	1.0	8
200	Bioavailability and Bioequivalence of Two Enteric-Coated Formulations of Omeprazole in Fasting and Fed Conditions. <i>Clinical Drug Investigation</i> , 2005, 25, 391-399.	1.1	26
201	Neuropharmacokinetic characterization of lamotrigine after its acute administration to rats. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2005, 27, 539.	0.8	6
202	Lamotrigine kidney distribution in male rats following a single intraperitoneal dose. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 51-55.	1.0	3
203	Pharmacokinetic-Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa. <i>Clinical Neuropharmacology</i> , 2004, 27, 17-24.	0.2	15
204	Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 603-609.	0.8	22
205	Relationship between plasma and brain levels and the anticonvulsant effect of lamotrigine in rats. <i>European Journal of Pharmacology</i> , 2003, 482, 163-168.	1.7	30
206	Hydrophilic and hydrophobic cyclodextrins in a new sustained release oral formulation of nicardipine: in vitro evaluation and bioavailability studies in rabbits. <i>Journal of Controlled Release</i> , 2003, 88, 127-134.	4.8	35
207	Population Pharmacokinetics of Digoxin in Pediatric Patients. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 742-745.	1.0	11
208	Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 215-222.	1.2	478
209	Influence of administration vehicles and drug formulations on the pharmacokinetic profile of lamotrigine in rats. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 331-336.	1.0	14
210	Population Kinetics of Tobramycin in Neonates. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 202-208.	1.0	12
211	Lamotrigine analysis in blood and brain by high-performance liquid chromatography. <i>Biomedical Applications</i> , 2001, 755, 119-127.	1.7	48
212	Theophylline pharmacokinetics with concomitant steroid and gold therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 191-195.	0.7	8
213	PKBase: A Population Approach-Oriented Database. <i>Annals of Pharmacotherapy</i> , 2000, 34, 123-124.	0.9	1
214	Predictive Capacity of Carbamazepine Pharmacokinetic Parameters in a Portuguese Outpatient Population. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 224-230.	1.0	6
215	Kinetic profile of carbamazepine in an adult Portuguese outpatient population. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998, 23, 315-321.	0.7	4
216	Population pharmacokinetics of caffeine in premature neonates. <i>European Journal of Clinical Pharmacology</i> , 1997, 52, 211-217.	0.8	52

#	ARTICLE	IF	CITATIONS
217	Carbamazepine Population Pharmacokinetics in Children. Therapeutic Drug Monitoring, 1997, 19, 132-139.	1.0	31
218	Therapeutic Monitoring of Theophylline—A Real Need!. Annals of Pharmacotherapy, 1992, 26, 1301-1302.	0.9	3